Mocuis and Supect® in Orlando for ASH 2015

mocuis-ash-2015-hematology

Orlando, FL – December 8, 2015

The 2015 American Society of Hematology (ASH) annual meeting commenced in sunny Orlando, FL from December 5-8.  ASH brings the world’s leading hematology specialists in one location.  With over 20,000 people from every sub-specialty, ASH 2015 was a success. Mocuis (모크스) was in Orlando for the heralded event joining the hematology community in sharing their meaningful information and conclusions.

PS15120800511g_99_20151208142306

ⓒ종합 경제정보 미디어 이데일리

Attendees of ASH took part in IL-Yang Pharm’s presentation of Supect’s® (Radotinib HCl) compelling Phase III efficacy and safety results for newly diagnosed CML-CP patients. Supect is a second generation tyrosine kinase inhibitor (TKI) approved in South Korea as a first line treatment for newly diagnosed chronic myeloid leukemia chronic phase (CML-CP) and for the treatment of patients with Philadelphia positive chronic myeloid leukemia (Ph+ CML) without optimal response and/or tolerance to other Bcr-Abl tyrosine kinase inhibitors.

#ASH15